http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie (ABBV) Issues US Regulatory Update on ABBV-951
-
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
-
AbbVie Declares Quarterly Dividend
-
AbbVie (ABBV) Appoints Roxanne S. Austin to its Board
-
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
-
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
-
AbbVie (ABBV) and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
-
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
-
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
-
AbbVie (ABBV) Announces Positive Topline Results from Phase 2 PICCOLO Trial of Mirvetuximab Soravtansine
-
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
-
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
-
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
-
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
-
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
-
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
-
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
-
AbbVie (ABBV) Receives Positive CHMP Opinion for Risankizumab
-
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
-
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
-
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
-
AbbVie (ABBV) Completes Acquisition of Landos
-
AbbVie Completes Acquisition of Landos Biopharma
-
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
-
AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
-
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
-
AbbVie to Present at the Bank of America Securities Healthcare Conference
-
AbbVie Reports First-Quarter 2024 Financial Results
-
AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
-
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
-
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
-
AbbVie (ABBV) Reports Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis
-
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
-
AbbVie (ABBV) Announces Data Supporting Long-Term Safety and Efficacy of Atogepant for Migraine
-
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
-
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
-
AbbVie to Host First-Quarter 2024 Earnings Conference Call
-
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
-
AbbVie (ABBV) to Acquire Landos Biopharma (LABP) for $20.42/Share
-
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
-
AbbVie (ABBV) Confirms FDA Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
-
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
-
ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
-
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
-
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
AbbVie (ABBV) Announces JUVEDERM VOLUMA XC For Temple Hollows Receives U.S. FDA Approval
-
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
-
AbbVie (ABBV) Pays Milestone to Dragonfly Following Dosing of First Patient in Phase 1 Trial of DF4101/ABBV-303
-
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
